Val
Torniamo alla LIRA
As a result of the spread of SARS-CoV-2, a global pandemic was declared.
Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people
with minimal danger of suffering serious complications due to COVID-19.
Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines
can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site.
These include the heart and brain, which may incur in situ production of spike protein
eliciting a strong autoimmunological inflammatory response.
Due to the fact that every human cell which synthesises non-self antigens,
inevitably becomes the target of the immune system,
and since the human body is not a strictly compartmentalised system,
accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed.
Therefore, our article aims to draw the attention of the scientific and regulatory communities
to the critical need for biodistribution studies for the genetic vaccines against COVID-19,
as well as for rational harm-benefit assessments by age group.
Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people
with minimal danger of suffering serious complications due to COVID-19.
Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines
can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site.
These include the heart and brain, which may incur in situ production of spike protein
eliciting a strong autoimmunological inflammatory response.
Due to the fact that every human cell which synthesises non-self antigens,
inevitably becomes the target of the immune system,
and since the human body is not a strictly compartmentalised system,
accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed.
Therefore, our article aims to draw the attention of the scientific and regulatory communities
to the critical need for biodistribution studies for the genetic vaccines against COVID-19,
as well as for rational harm-benefit assessments by age group.